Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 2,399 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 2,399 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $40.83, for a total transaction of $97,951.17. Following the transaction, the general counsel now owns 47,088 shares of the company’s stock, valued at approximately $1,922,603.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jeff Cislini also recently made the following trade(s):

• On Wednesday, June 26th, Jeff Cislini sold 2,000 shares of Revolution Medicines stock. The stock was sold at an average price of $38.47, for a total transaction of $76,940.00.

Revolution Medicines Stock Down 3.3 %

Shares of Revolution Medicines stock traded down $1.46 on Wednesday, hitting $42.46. The stock had a trading volume of 1,538,144 shares, compared to its average volume of 1,350,429. The stock has a market cap of $7.01 billion, a price-to-earnings ratio of -11.71 and a beta of 1.44. Revolution Medicines, Inc. has a twelve month low of $15.44 and a twelve month high of $44.80. The business’s 50 day moving average is $38.76 and its two-hundred day moving average is $33.61.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.05. During the same period last year, the business earned ($0.72) earnings per share. The business’s quarterly revenue was down 100.0% compared to the same quarter last year. As a group, equities analysts predict that Revolution Medicines, Inc. will post -3.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RVMD. Wedbush upped their target price on Revolution Medicines from $42.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, May 9th. Oppenheimer increased their price objective on Revolution Medicines from $43.00 to $45.00 and gave the company an “outperform” rating in a report on Friday, April 12th. HC Wainwright restated a “buy” rating and set a $44.00 target price on shares of Revolution Medicines in a report on Monday, May 13th. Raymond James upgraded shares of Revolution Medicines from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $36.00 to $48.00 in a research note on Wednesday, April 10th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $46.00 price objective on shares of Revolution Medicines in a research report on Thursday, May 9th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $45.00.

Institutional Trading of Revolution Medicines

A number of institutional investors have recently bought and sold shares of RVMD. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Revolution Medicines in the third quarter valued at approximately $830,000. Walleye Capital LLC bought a new stake in shares of Revolution Medicines during the 3rd quarter valued at $2,644,000. Wellington Management Group LLP grew its holdings in shares of Revolution Medicines by 2.7% during the 3rd quarter. Wellington Management Group LLP now owns 10,572,475 shares of the company’s stock worth $292,646,000 after purchasing an additional 282,786 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Revolution Medicines by 3.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,643,591 shares of the company’s stock worth $266,935,000 after purchasing an additional 303,088 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its position in shares of Revolution Medicines by 242.4% in the fourth quarter. Exchange Traded Concepts LLC now owns 11,282 shares of the company’s stock worth $324,000 after purchasing an additional 7,987 shares during the period. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.